REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

Resources for healthcare professionals and patients

Here, you can access tools and other resources that you and your patients may find helpful for learning more about REVLIMID. Check back for updates as new resources become available.


Medication Guide

Read the Medication Guide and help patients understand the potential side effects associated with REVLIMID treatment.


Patient Brochure

A guide for patients with relapsed or refractory mantle cell lymphoma.


Full Prescribing Information

Explore the full Prescribing Information, including Boxed WARNINGS.


Resources for patients and caregivers.

This list of independent organizations is provided as an additional resource for obtaining information related to mantle cell lymphoma (MCL). Inclusion on this list does not indicate endorsement by Celgene Corporation, a Bristol Myers Squibb company, of an organization or its communications.

Patient support groups

American Cancer Society

Leukemia & Lymphoma Society®

Lymphoma Research Foundation

National Cancer Institute
(800-4-CANCER) (800-422-6237)

Resources for caregivers

Association of Cancer Online Resources


Family Caregiver Alliance®

National Alliance for Caregiving
(online only)

National Coalition for Cancer Survivorship

Caregiver Action Network

Well Spouse® Association

Learn more about the Lenalidomide REMS program.

Find Out Now